1Faculty of Dentistry, Spain
2Department of Dental Clinical Specialties, Spain
3Proffesor at Department of Dental Clinical Specialties, Spain
*Corresponding author:Fabián Pérez González, Department of Conservative Dentistry and Orofacial Prosthodontics, Faculty of Dentistry, Spain
Submission: July 03, 2019 Published: July 19, 2019
Background: Bisphosphonates (BP) are a group of drugs used in treatment and prevention of alterated turn-over of bone diseases. Since 2003, it is known That BP are able to develop osteonecrosis of the jaw (BRONJ: Bisphosphonate-Related Osteonecrosis of the Jaw) when they are associated to any surgical trauma, even dental implant therapy.
Materials and Methods: Comprehensive research of scientific articles from ten years ago to our days in Medline (Pubmed).
Results and Discussion: 1090 dental implants placed patients treated with BP and 3472 dental implants placed in healthy patients had successfully rates of 97.6% and 97.9%, respectively. Therefore, implant placement in patients in treatment with BP does not reduce implant success rates. Besides, BRONJ appears before with intravenous vs oral administration of BP.
Conclusion: Further well-designed long-term studies are necessary to evaluate correctly the relationship between BP and dental implants.
Keywords: Dental implant; Osteonecrosis; Bisphosphonate; Bisphosphonate-related osteonecrosis of the jaw
Abbreviations: BP: Bisphosphonates; BRONJ: Bisphosphonate Related Osteonecrosis of the Jaw; CTX: C Terminal Telopeptide, TCT; AAOMS: The American Association of Oral and Maxillofacial Surgeons